Given Imaging — Investor Presentation (January 2012)
37 slides from Given Imaging's investor presentation, Jan 9, 2012
Slide 1: January 2012
January 2012
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, projections about our business and our fu
Slide 3: Revolutionizing How GI Diseases are Screened, Diagnosed and Monitored
Revolutionizing How GI Diseases are Screened, Diagnosed and Monitored
Slide 4: Given Imaging: Advancing GI
Multi-Billion $ Market Opportunity Expand Core Business Commercialize PillCam COLON Acquire Complementary Products Given Imaging: Advancing GI
Slide 5: Digitrapper pH-Z ManoScan High-resolution manometry PillCam SB Most widely-used tool for small bowel PillCam
Digitrapper pH-Z ManoScan High-resolution manometry PillCam SB Most widely-used tool for small bowel PillCam COLON Patient-friendly complement to colonoscopy PillCam ESO Patient-friendly tool for visualization of the esophagus
Slide 6: Global Footprint Supports Growth
Global Footprint Supports Growth 760 Employees Worldwide ◦ N. America: 99 reps ◦ EMEA: 24 reps ◦ Australia: 9 reps ◦ Asia (ex. Japan): 5 reps + Distributors ◦ Brazil: going direct Distributors in over 60 countries worldwide One of the Largest GI Sales Forces in North America Direct Sales and Marketi
Slide 7: Strong Track Record of Growth and Profitability
Strong Track Record of Growth and Profitability Revenue and Gross Margin Growth Recurring revenue model drives growth/high margins Diversified, growing revenues Strong, debt-free balance sheet: $100m in cash and equivalents Strong operating cash flow $175* *Midpoint of guidance
Slide 8: Global Market Leadership
Global Market Leadership More than 1,600 PillCam peer reviewed publications More than 1.5 million PillCams ingested ~300 registered patents ~320 pending patents *Company estimates US Market Share * : 95% Global Market Share * : 85%
Slide 9: GI Market Growth Drivers
GI Market Growth Drivers GI Non-GI Dyspepsia 20-25% Hypertension 28% IBS 10-25% Migraine headache 6-18% GERD 16% Asthma 8% Chronic Constipation 12-19% Diabetes 8% • Aging global population ◦ Today 500 million people or 8% of world population are > 65 1 ◦ In 2020, 1 billion or 13% of the total popula
Slide 10: Extensive Clinical Program Supports Future Growth
Extensive Clinical Program Supports Future Growth ONE OF THE LARGEST PROGRAMS IN GI Product Disease State Total Sponsored # of Sites # of Pts PillCam COLON CRC / Colonic Diseases 17 4 62 2,625 PillCam SB OGIB/SB 6 2 21 1,290 Reflux Manometry pH/GERD 3 0 11 579 PillCam SB IBD 13 3 41 550 PillCam ESO
Slide 11: Maximizing the PillCam SB Opportunity
Maximizing the PillGam SB Opportunity
Slide 12: Benefits of PillCam SB
Benefits of PillCam SB Patients Non-invasive No sedation Easy to administer and ingest No lost work time, instant recovery Physicians Broad and favorable reimbursement worldwide Average US reimbursement of $945 Average reading time 30 minutes
Slide 13: PillCam SB: A $1 Billion Opportunity
PillCam SB: A $1 Billion Opportunity Global Revenue Opportunity / Penetration 40% OUS 60% US OUS market growing 18-20% Significant potential: 90% of market un-penetrated Grow US sales: Increase physician use in expanded indications
Slide 14: Crohn's Disease - A Disease of the Small Bowel
Crohn’s Disease - A Disease of the Small Bowel Source: Engstrom PF., Goosenberg EB. Diagnosis and Management of Bowel Diseases. Professional Communication Publishers 1999: 172-173. of all patients have small bowel involvement ~40% of cases: SMALL BOWEL & COLON ~30% of cases: SMALL BOWEL ONLY ~70% ~3
Slide 15: Expanding PillCam Use in Crohn's Detection and Monitoring in US
Expanding PillCam Use in Crohn’s Detection and Monitoring in US ▪ Accelerate the adoption of PillCam SB as the preferred Crohn’s disease patient management tool PRIORITIES: 1. Drive commercial programs to increase awareness and penetrate the CD patient management algorithm § Fully leverage resources
Slide 16: International reimbursement and expansion
France º Significant hardware and capsule growth with reimbursement in place for entire 63 million population Germany º February 2011, German Health Ministry announced intent to establish PillCam SB reimbursement code º 73 million Germans to be fully reimbursed in 2012/2013 º Several sickness funds
Slide 17: Growing the GI Functional Diagnostics Market
— — =e Growing the } ,=\\ 3 GI Functional : Ur IOS Diagnostics Market
Slide 18: Solid Outlook for GI Functional Diagnostics Business
Solid Outlook for GI Functional Diagnostics Business • Complementary portfolio of products accretive to top and bottom lines • 18% increase in revenue April - Sept 2011 vs. same period in 2010 • Double digit revenue growth expected in 2012 • ~ 26% of total revenues and growing • Expand footprint amo
Slide 19: PillCam COLON not cleared for use in U.S.
PillCam COLON not cleared for use in U.S.
Slide 20: Colorectal Cancer Facts
Colorectal Cancer Facts • Screening guidelines ◦ In the US and major European countries, every adult >50 years should be screened ◦ In Japan, every adult >40 years should be screened ◦ Compliance 50-60% in US, <25% in Europe, Japan • Approximately 30 million colonoscopies per year globally 1.2 milli
Slide 21: PillCam COLON Global Opportunity
PillCam COLON Global Opportunity Annualized addressable procedures SCREENING: DIAGNOSTIC: 7.7 million 3.3 million $4 Billion Target Market Source: Company estimates based on addressable procedures in US, Japan, France, Italy, Germany, UK, Spain.
Slide 22: PillCam COLON: A Sizable Target Market
PillCam COLON: A Sizable Target Market PillCam COLON is complementary to colonoscopy Screening Individuals unwilling to get a screening colonoscopy Diagnostic Patients unable to undergo colonoscopy or at higher risk for complications
Slide 23: PillCam COLON: Two Paths to Success
Diagnostic tool for symptomatic patients PillCam COLON: Two Paths to Success Screening 19% of patients at a higher risk of bleeding or respiratory failure due to sedation with colonoscopy • 5-10% of patients have prior incomplete colonoscopy • Patients with positive FOBT, refusing colonoscopy First
Slide 24: The PillCam COLON Solution
The PillCam COLON Solution Colonoscopy Flex Sigmoidoscopy Barium Enema sDNA FIT gFOBT Virtual Colonoscopy Blood Test PillCam COLON HIGH Invasiveness HIGH Accuracy (Detect Cancer & Polyps) LOW Invasiveness LOW Accuracy (Detect Cancer) Key: = Indirect information = Direct visualization
Slide 25: Recent Trials Underscore Value of PillCam COLON
Recent Trials Underscore Value of PillCam COLON 2 CRC Screening Test Sensitivity Specificity Stool Test 10-30% ~95% Double Contrast Barium Enema 40-48% ~90% CT Colonography 80-90% 90-95% Flexible Sigmoidoscopy 35-50% ~95% Colonoscopy 85%+ ~95% PillCam COLON 2* 88% 89-95% PillCam COLON 2 offers compe
Slide 26: PillCam COLON Provides Excellent Visualization
PillCam COLON Provides Excellent Visualization
Slide 27: PillCam COLON an Appealing Option to Patients
PillCam COLON an Appealing Option to Patients Based on the information available to you, which screening test would you chose for yourself? Colon Capsule Endoscopy, Colonoscopy, Stool test, or Nothing. Assume all product costs are covered by insurance (cost is comparable). (n=308) % of Patients Sele
Slide 28: PillCam COLON May Increase Colonoscopy Compliance
PillCam COLON May Increase Colonoscopy Compliance Given Imaging market research (n=300) non-compliant patients
Slide 29: GIs Show Increased Willingness to Use PillCam COLON
GIs Show Increased Willingness to Use PillCam COLON AFTER Presentation PillCam COLON gained share at the expense of colonoscopy, FIT, and CTC Poll of approximately 450 GI attendees at UEGW 2011 BEFORE Presentation “You are 50 years old - you are persuaded to do a screening test for CRC. Which of the
Slide 30: Commercializing PillCam COLON
Commercializing PillCam COLON Europe US Japan • 2012 broad European launch • Distribute colon capsule endoscopy consensus guidelines • 800+ patient pivotal trial underway: 700 patients enrolled, 500 ingestions • Enrollment expected to be completed by end of Q2 • 72 patient pivotal trial underway • T
Slide 31: PillCam COLON Path to Patients
PillCam COLON Path to Patients 4Q 2012 3Q 2012 2Q 2012 1Q 2012
Slide 32: Expanding Our Platform: Passive to Active
Expanding Our Platform: Passive to Active
Slide 33: Solid Growth and Profitability
WEN Solid Growth \ f rahi and Profitability
Slide 34: Given Imaging Revenue Trajectory
Given Imaging Revenue Trajectory Revenue Growth Potential ~ 2.5x increase $175* *Midpoint of guidance
Slide 35: Financial Strength
Financial Strength Product YTD Sept. 2010 YTD Sept. 2011 2011 Guidance Non-GAAP Gross Margin 77.3% 77.0% Non-GAAP EPS $0.45 $0.40 $0.65-$0.70 GAAP EPS $0.17 $0.20 $0.35-$0.40 • Diversified, growing revenue stream • Strong, debt-free balance sheet • Sustainable cash generation • $100 million in cash,
Slide 36: Given Imaging: Advancing GI
Given Imaging: Advancing GI • PillCam SB: Gold standard ◦ Standard of care for diagnosing small bowel disorders, ~74% of total revenues o 95% US market share, 85% global o Significant upside in geographic expansion and new indications (i.e., Crohn’s disease) • Demonstrated M&A expertise ◦ Successful
Slide 37: NASDAQ: GIVN
NASDAQ: GIVN